Evaluation Of Helicobacter pylori Antigen Positivity İn Stool Samples Of Patients With Dyspeptic Complaints
Abstract
Abstract Helicobacter pyloriis a bacterium that has been implicated in the gastrointestinal tractand responsible for important clinical tables throughout mankind history. There is a strongrelationship between gastric cancer and H.pyloripositivity. In this study, we intendedto establish the positivity rate of H.pyloriantigen in stool samples of outpatients withdyspeptic complaints and to evaluate its relation with age and gender. Between January 01, 2014 and February 28, 2018, stool samples of 1142 outpatients with dyspepticcomplaints admitted to various departments are investigated with an immunochromatographic test kit using monoclonal antibodies for detection of H.pyloriantigen. The results were evaluated retrospectively. Among 1142 patients’ stool samples tested, 125(10.9%) were positive. Among all cases, 740 (64.7%) were under 40 years of age. 35.2%of men and 64.8% of women were detected as positive. According to age groups, 40% patients were positive for 20-40 age groups. When compared with other studies in Turkey, it is a pleasing result to detect a lower rate of positivity.
References
- Kaynaklar 1. Lawson AJ. Helicobacter. “Jorgensen JH, Landry ML, Warnock DW(eds): Manual of Clinical Microbiology, 10. baskı” kitabında s. 900-15, ASM Press, Washington DC (2011) 2. Jones NL, Sherman P, Fallone CA, Flook N, Smaill F: Canadian He-licobacter Study Group Consensus Conference: update on the appro-ach to Helicobacter pylori infection in children and adolescents—anevidence-based evaluation. Can J Gastroenterol 2005, 19 (7): 399-408 3. Yang HR, Seo JK. Helicobacter pylori stool antigen (HpSA) tests inchildren before and after eradication therapy: Comparison of rapidimmunochromatographic assay and HpSA ELISA. Dig Dis Sci2007;53(8):2053-8 4. Malfertheiner P, Megraud F, O'Morain CA on behalf of the Europe-an Helicobacter and Microbiota Study Group and Consensus panel,et al Management of Helicobacter pylori infection—the MaastrichtV/Florence Consensus Report Gut 2017;66:6-30 5. IARC Helicobacter pylori Working Group (2014). Helicobacter pylo-ri Eradication as a Strategy for Preventing Gastric Cancer. Lyon,France: International Agency for Research on Cancer (IARC Wor-king Group Reports, No. 8). Available from: http://www.iarc.fr/en/pub-lications/pdfsonline/wrk/wrk8/index.php 6. Erdem L, Akbayır N, Sakız D, Alkım C, Sökmen HM, Karaca Ç, etal. Dispepsili hastalarda midenin prekanseröz lezyonları ile karşı-laşma riski. Akademik Gastroenteroloji Dergisi 2005; 4 (2): 78-82 7. Tkachenko MA, Zhannat NZ, Erman LV, Blashenkova EL, Isachen-ko SV, Isachenko OB, et al. Dramatic changes in the prevalence ofHelicobacter pylori infection during childhood: a 10-year follow-upstudy in Russia. J Pediatr Gastroenterol Nutr 2007; 45(4): 428-32 8. Chen J, Bu XL, Wang QY, Hu PJ. and Chen MH. Decreasing Serop-revalence of Helicobacter pylori Infection during 1993–2003 in Gu-angzhou, Southern China. Helicobacter 2007; 12: 164–169 9. Aguemon BD, Struelens MJ, Massougbodji A, Ouendo EM: Prevalen-ce and risk- factors for Helicobacter pylori infection in urban and ru-ral Beninese populations. Clin Microbiol Infect 2005, 11(8): 611-617 10. Ozaydin N, Turkyilmaz SA, Cali S. Prevalence and risk factors of He-licobacter pylori in Turkey: a nationally-representative, cross-sec-tional, screening with the 13C-Urea breath test. BMC Public Health2013;13: 1215 11. Leal YA, Roberto CR, Abraham SJ, Juan RV, Laura LF, Javier T. Uti-lity of stool sample–based tests for the diagnosis of Helicobacter pylo-ri infection in children. J Pediatric Gastro Nutrition 2011;52: 718–728 12. Ana Isabel Lopes, Filipa F Vale, Mónica Oleastro. Helicobacter pylo-ri infection - recent developments in diagnosis. World J Gastroen-terol 2014; 28; 20(28): 9299-9313 13. Çalık Z, Karamese M, Acar O, Karamese SA, Dicle Y, Albayrak F,et al. Investigation of Helicobacter pylori antigen in stool samplesof patients with upper gastrointestinal complaints. Braz J Microbi-ol 2016; 47(1): 167-171. 14. Demir T,Turan M, Tekin A. Kırşehir bölgesindeki dispeptik hastalar-da Helicobacter pylori antijen prevalansı. Dicle Med J 2011; 38 (1):44-48 15. Çıkman A, Parlak M, Güdücüoğlu H, Berktaş M. Van yöresinde He-licobacter pylori prevalansı, yaş ve cinsiyete göre dağılımı. ANKEMDerg 2012; 26(1): 30-34 16. Selek MB, Bektöre B, Atik TK, Baylan O, Özyurt M. Evaluation ofHelicobacter pylori antigen positivity in stool samples of patients withdyspeptic complaints in a tertiary care hospital. Dicle Med J 2013;40 (4): 574-578 17. Lee YC, Chiang TH, Chou CK, et al. Association between Helicobac-ter pylori eradication and gastric cancer incidence: a systematic re-view and meta-analysis. Gastroenterology 2016; 150.5: 1113-1124.) 18. Teng AM, Kvizhinadze G, Nair N, McLeod M, Wilson N, Blakely T.A screening program to test and treat for Helicobacter pylori infec-tion: Cost-utility analysis by age, sex and ethnicity. BMC Infect Dis2017; 17: 156 19. Lario S, Ramírez-Lázaro MJ, Montserrat A, Quílez ME, Junquera F,Martínez-Bauer E Diagnostic accuracy of three monoclonal stool testsin a large series of untreated Helicobacter pylori infected patients.Clin Biochem. 2016; 49(9): 682-687. 20. Areia M, Carvalho R, Cadime AT, et al. Screening for gastric can-cer and surveillance of premalignant lesions: a systematic review ofcost
Dispeptik Yakınmaları Olan Hastaların Dışkı Örneklerinde Helicobacter pylori Antijen Pozitifliğinin Değerlendirilmesi
Abstract
Öz
Helicobacter pyloriinsanlık tarihi boyunca gastrointestinal sistemde yerleşen ve önemli klinik tablolardan sorumlu bir bakteridir. Gastrik kanser ile H.pyloripozitifliği arasında güçlü bir ilişki olduğu kanıtlanmıştır. Bu çalışmada, dispeptik yakınmalara sahip hastaların dışkı örneklerinde H.pyloriantijeninin pozitiflik oranını belirlemek ve yaş ve cinsiyet ile olan ilişkisini değerlendirmek amaçlanmıştır. Ocak 2014–Şubat 2018 tarihleri arasında, dispeptik yakınmaları nedeniyle çeşitli polikliniklere başvuran 1142 hastanın gaita örneği, H.pyloriantijeninin tespiti için monoklonal antikor içeren immunokromatografik test kitleri ile araştırılmıştır. Sonuçlar retrospektif olarak değerlendirilmiştir. İncelenen gaita örnekleri arasında 125/1142 (%10.9)'si immunoassay yöntemiyle pozitif olarak sonuçlandı. Olguların 740 (%64.7)'ı 40 yaşından küçüktür. Sonucu pozitifolan olguların 44 (%35.2)'ü erkek, 81 (%64.8)'i kadın idi. Özellikle 20-40 yaş aralığın-da 50 pozitif hasta (%40) tespiti ile tüm yaş grupları arasında en yüksek oran bulunmuştur. Türkiye’den diğer çalışmalar ile kıyaslandığı zaman, daha düşük pozitiflik oranı tespit edilmesi sevindirici bir sonuçtur
References
- Kaynaklar 1. Lawson AJ. Helicobacter. “Jorgensen JH, Landry ML, Warnock DW(eds): Manual of Clinical Microbiology, 10. baskı” kitabında s. 900-15, ASM Press, Washington DC (2011) 2. Jones NL, Sherman P, Fallone CA, Flook N, Smaill F: Canadian He-licobacter Study Group Consensus Conference: update on the appro-ach to Helicobacter pylori infection in children and adolescents—anevidence-based evaluation. Can J Gastroenterol 2005, 19 (7): 399-408 3. Yang HR, Seo JK. Helicobacter pylori stool antigen (HpSA) tests inchildren before and after eradication therapy: Comparison of rapidimmunochromatographic assay and HpSA ELISA. Dig Dis Sci2007;53(8):2053-8 4. Malfertheiner P, Megraud F, O'Morain CA on behalf of the Europe-an Helicobacter and Microbiota Study Group and Consensus panel,et al Management of Helicobacter pylori infection—the MaastrichtV/Florence Consensus Report Gut 2017;66:6-30 5. IARC Helicobacter pylori Working Group (2014). Helicobacter pylo-ri Eradication as a Strategy for Preventing Gastric Cancer. Lyon,France: International Agency for Research on Cancer (IARC Wor-king Group Reports, No. 8). Available from: http://www.iarc.fr/en/pub-lications/pdfsonline/wrk/wrk8/index.php 6. Erdem L, Akbayır N, Sakız D, Alkım C, Sökmen HM, Karaca Ç, etal. Dispepsili hastalarda midenin prekanseröz lezyonları ile karşı-laşma riski. Akademik Gastroenteroloji Dergisi 2005; 4 (2): 78-82 7. Tkachenko MA, Zhannat NZ, Erman LV, Blashenkova EL, Isachen-ko SV, Isachenko OB, et al. Dramatic changes in the prevalence ofHelicobacter pylori infection during childhood: a 10-year follow-upstudy in Russia. J Pediatr Gastroenterol Nutr 2007; 45(4): 428-32 8. Chen J, Bu XL, Wang QY, Hu PJ. and Chen MH. Decreasing Serop-revalence of Helicobacter pylori Infection during 1993–2003 in Gu-angzhou, Southern China. Helicobacter 2007; 12: 164–169 9. Aguemon BD, Struelens MJ, Massougbodji A, Ouendo EM: Prevalen-ce and risk- factors for Helicobacter pylori infection in urban and ru-ral Beninese populations. Clin Microbiol Infect 2005, 11(8): 611-617 10. Ozaydin N, Turkyilmaz SA, Cali S. Prevalence and risk factors of He-licobacter pylori in Turkey: a nationally-representative, cross-sec-tional, screening with the 13C-Urea breath test. BMC Public Health2013;13: 1215 11. Leal YA, Roberto CR, Abraham SJ, Juan RV, Laura LF, Javier T. Uti-lity of stool sample–based tests for the diagnosis of Helicobacter pylo-ri infection in children. J Pediatric Gastro Nutrition 2011;52: 718–728 12. Ana Isabel Lopes, Filipa F Vale, Mónica Oleastro. Helicobacter pylo-ri infection - recent developments in diagnosis. World J Gastroen-terol 2014; 28; 20(28): 9299-9313 13. Çalık Z, Karamese M, Acar O, Karamese SA, Dicle Y, Albayrak F,et al. Investigation of Helicobacter pylori antigen in stool samplesof patients with upper gastrointestinal complaints. Braz J Microbi-ol 2016; 47(1): 167-171. 14. Demir T,Turan M, Tekin A. Kırşehir bölgesindeki dispeptik hastalar-da Helicobacter pylori antijen prevalansı. Dicle Med J 2011; 38 (1):44-48 15. Çıkman A, Parlak M, Güdücüoğlu H, Berktaş M. Van yöresinde He-licobacter pylori prevalansı, yaş ve cinsiyete göre dağılımı. ANKEMDerg 2012; 26(1): 30-34 16. Selek MB, Bektöre B, Atik TK, Baylan O, Özyurt M. Evaluation ofHelicobacter pylori antigen positivity in stool samples of patients withdyspeptic complaints in a tertiary care hospital. Dicle Med J 2013;40 (4): 574-578 17. Lee YC, Chiang TH, Chou CK, et al. Association between Helicobac-ter pylori eradication and gastric cancer incidence: a systematic re-view and meta-analysis. Gastroenterology 2016; 150.5: 1113-1124.) 18. Teng AM, Kvizhinadze G, Nair N, McLeod M, Wilson N, Blakely T.A screening program to test and treat for Helicobacter pylori infec-tion: Cost-utility analysis by age, sex and ethnicity. BMC Infect Dis2017; 17: 156 19. Lario S, Ramírez-Lázaro MJ, Montserrat A, Quílez ME, Junquera F,Martínez-Bauer E Diagnostic accuracy of three monoclonal stool testsin a large series of untreated Helicobacter pylori infected patients.Clin Biochem. 2016; 49(9): 682-687. 20. Areia M, Carvalho R, Cadime AT, et al. Screening for gastric can-cer and surveillance of premalignant lesions: a systematic review ofcost
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Makaleler 1 |
| Authors | |
| Publication Date | February 4, 2018 |
| Published in Issue | Year 2018 Volume: 6 Issue: 2 |
